~(18)F-FDG PET/CT对食管癌新辅助放化疗后组织病理学反应预测的研究进展
|
摘要
晚期食管癌患者预后差,病死率高,与单独手术相比,术前新辅助放化疗可能有助于改善患者生存,新辅助放化疗无效者应早期手术切除。因此,早期准确无创地评估新辅助放化疗的反应有重要价值。采用~(18) F-氟代脱氧葡萄糖(~(18)F-fluorodeoxyglucose,~(18)F-FDG)正电子发射计算机断层显像(positron emission tomography,PET)/CT预测新辅助放化疗后组织病理学反应可能有助于治疗方案的选择及指导个体化治疗。本文就~(18)F-FDG PET/CT在食管癌新辅助放化疗后组织病理学反应预测的研究进展作一综述。
Patients with advanced esophageal cancer have a poor prognosis and high mortality,and preoperative neoadjuvant chemoradiotherapy may improve the survival compared with esophagectomy alone.The patients with no response to neoadjuvant treatment should be performed earlier surgical resection.Therefore,the early and accurate noninvasive assessment of response to neoadjuvant treatment is extremely important.The use of ~(18) F-FDG positron emission tomography(PET)/CT in the prediction of histopathologic response to neoadjuvant chemoradiotherapy in patients with esophageal carcinoma may contribute to the choice of the follow-up treatment and guidance on individualized treatment strategies.This paper reviews the research progress of the predictive value of ~(18) F-FDG PET/CT to histopathologic response to neoadjuvant chemoradiotherapy in patients with esophageal carcinoma.
Patients with advanced esophageal cancer have a poor prognosis and high mortality,and preoperative neoadjuvant chemoradiotherapy may improve the survival compared with esophagectomy alone.The patients with no response to neoadjuvant treatment should be performed earlier surgical resection.Therefore,the early and accurate noninvasive assessment of response to neoadjuvant treatment is extremely important.The use of ~(18) F-FDG positron emission tomography(PET)/CT in the prediction of histopathologic response to neoadjuvant chemoradiotherapy in patients with esophageal carcinoma may contribute to the choice of the follow-up treatment and guidance on individualized treatment strategies.This paper reviews the research progress of the predictive value of ~(18) F-FDG PET/CT to histopathologic response to neoadjuvant chemoradiotherapy in patients with esophageal carcinoma.
引文
[1]JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2]ALLUM W H,STENNING S P,BANCEWICZ J,et al.Longterm results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer[J].J Clin Oncol,2009,27(30):5062-5067.
[3]SCHNEIDER P M,BALDUS S E,METZGER R,et al.Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer:implications for response classification[J].Ann Surg,2005,242(5):684-692.
[4]SJOQUIST K M,BURMEISTER B H,SMITHERS B M,et al.Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.
[5]彭良群,杨巍,张占东,等.进展期胃癌患者新辅助化疗后病理完全缓解的影响因素[J].中华实用诊断与治疗杂志,2017,31(7):697-699.
[6]VALLBOHMER D,HOLSCHER A H,DEMEESTER S,et al.A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0esophageal cancer[J].Ann Surg,2010,252(5):744-749.
[7]KWEE R M,MARCUS C,SHEIKHBAHAEI S,et al.PETwith fluorodeoxyglucose F ~(18)/computed tomography in the clinical management and patient outcomes of esophageal cancer[J].PET Clin,2015,10(2):197-205.
[8]LU J,SUN X D,YANG X,et al.Impact of PET/CT on radiation treatment in patients with esophageal cancer:a systematic review[J].Crit Rev Oncol Hematol,2016,107:128-137.
[9]CREMONESI M,GARIBALDI C,TIMMERMAN R,et al.Interim ~(18)F-FDG-PET/CT during chemoradiotherapy in the management of oesophageal cancer patients:a systematic review[J].Radiother Oncol,2017,125(2):200-212.
[10]冯峰,夏淦林,强福林,等.~(18) F-FDG PET/CT对乳腺癌术后复发转移的诊断价值[J].中华实用诊断与治疗杂志,2015,29(9):913-915.
[11]薛丹丹,史大鹏.肺癌患者Ki-67阳性表达与~(18) F-脱氧葡萄糖PET/CT最大标准摄入值的关系[J].中华实用诊断与治疗杂志,20~(18),32(10):968-970.
[12]FLAMEN P,LERUT A,VAN CUTSEM E,et al.The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer[J].J Thorac Cardiovasc Surg,2000,120(6):1085-1092.
[13]BRUZZI J F,MUNDEN R F,TRUONG M T,et al.PET/CTof esophageal cancer:its role in clinical management[J].Radiographics,2007,27(6):1635-1652.
[14]HAN D,YU J,YU Y,et al.Comparison of ~(18)F-fluorothymidine and ~(18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus[J].Int JRadiat Oncol Biol Phys,2010,76(4):1235-1241.
[15]杭达明,成国建,储开岳,等.PET-CT对食管癌临床分期及在调强放疗中的应用[J].中华实用诊断与治疗杂志,2013,27(4):368-370.
[16]SHI W,WANG W,WANG J,et al.Meta-analysis of ~(18)FDGPET-CT for nodal staging in patients with esophageal cancer[J].Surg Oncol,2013,22(2):112-116.
[17]ZHU W,XING L,YUE J,et al.Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis[J].Br JRadiol,2012,85(1017):e694-e701.
[~(18)]MANDARD A M,DALIBARD F,MANDARD J C,et al.Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma:clinicopathologic correlations[J].Cancer,1994,73(11):2680-2686.
[19]Japan Esophageal Society.Japanese Classification of Esophageal Cancer,11th Edition:partⅡandⅢ[J].Esophagus,2017,14(1):37-65.
[20]DARNTON S J,ALLEN S M,EDWARDS C W,et al.Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy[J].J Clin Pathol,1993,46(1):51-55.
[21]VAN HAGEN P,HULSHOF M C,VAN LANSCHOT J J,et al.Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.
[22]MALTHANER R A,COLLIN S,FENLON D.Preoperative chemotherapy for resectable thoracic esophageal cancer[J].Cochrane Database Syst Rev,2006(3):D1556.
[23]BEUKINGA R J,HULSHOFF J B,VAN DIJK L V,et al.Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pretreatment ~(18)F-FDG PET/CT imaging[J].J Nucl Med,2017,58(5):723-729.
[24]KWEE R M.Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of ~(18)F-FDGPET:a systematic review[J].Radiology,2010,254(3):707-717.
[25]CHEN Y M,PAN X F,TONG L J,et al.Can ~(18)F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in esophageal cancer patients?A meta-analysis[J].Nucl Med Commun,2011,32(11):1005-1010.
[26]SCHREURS L M,JANSSENS A C,GROEN H,et al.Value of EUS in determining curative resectability in reference to CTand FDG-PET:the optimal sequence in preoperative staging of esophageal cancer?[J].Ann Surg Oncol,2016,23(Suppl 5):1021-1028.
[27]CONG L,WANG S,GAO T,et al.The predictive value of~(18)F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy:a meta-analysis[J].Jpn J Clin Oncol,2016,46(12):11~(18)-1126.
[28]MALIK V,LUCEY J A,DUFFY G J,et al.Early repeated~(18)F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus[J].J Nucl Med,2010,51(12):~(18)63-~(18)69.
[29]VAN HEIJL M,OMLOO J M,VAN BERGE H M,et al.Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer[J].Ann Surg,2011,253(1):56-63.
[30]NAKAJO M,JINGUJI M,NAKABEPPU Y,et al.Texture analysis of ~(18)F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy[J].Eur J Nucl Med Mol Imaging,2017,44(2):206-214.
[31]YANAGAWA M,TATSUMI M,MIYATA H,et al.Evaluation of response to neoadjuvant chemotherapy for esophageal cancer:PET response criteria in solid tumors versus response evaluation criteria in solid tumors[J].J Nucl Med,2012,53(6):872-880.
[32]DE COBELLI F,GIGANTI F,ORSENIGO E,et al.Apparent diffusion coefficient modifications in assessing gastrooesophageal cancer response to neoadjuvant treatment:comparison with tumour regression grade at histology[J].Eur Radiol,2013,23(8):2165-2174.
[33]魏路,姚峰.表观遗传调控在新辅助化疗中作用的研究进展[J].中华实用诊断与治疗杂志,20~(18),32(11):1141-1144.
[2]ALLUM W H,STENNING S P,BANCEWICZ J,et al.Longterm results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer[J].J Clin Oncol,2009,27(30):5062-5067.
[3]SCHNEIDER P M,BALDUS S E,METZGER R,et al.Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer:implications for response classification[J].Ann Surg,2005,242(5):684-692.
[4]SJOQUIST K M,BURMEISTER B H,SMITHERS B M,et al.Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.
[5]彭良群,杨巍,张占东,等.进展期胃癌患者新辅助化疗后病理完全缓解的影响因素[J].中华实用诊断与治疗杂志,2017,31(7):697-699.
[6]VALLBOHMER D,HOLSCHER A H,DEMEESTER S,et al.A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0esophageal cancer[J].Ann Surg,2010,252(5):744-749.
[7]KWEE R M,MARCUS C,SHEIKHBAHAEI S,et al.PETwith fluorodeoxyglucose F ~(18)/computed tomography in the clinical management and patient outcomes of esophageal cancer[J].PET Clin,2015,10(2):197-205.
[8]LU J,SUN X D,YANG X,et al.Impact of PET/CT on radiation treatment in patients with esophageal cancer:a systematic review[J].Crit Rev Oncol Hematol,2016,107:128-137.
[9]CREMONESI M,GARIBALDI C,TIMMERMAN R,et al.Interim ~(18)F-FDG-PET/CT during chemoradiotherapy in the management of oesophageal cancer patients:a systematic review[J].Radiother Oncol,2017,125(2):200-212.
[10]冯峰,夏淦林,强福林,等.~(18) F-FDG PET/CT对乳腺癌术后复发转移的诊断价值[J].中华实用诊断与治疗杂志,2015,29(9):913-915.
[11]薛丹丹,史大鹏.肺癌患者Ki-67阳性表达与~(18) F-脱氧葡萄糖PET/CT最大标准摄入值的关系[J].中华实用诊断与治疗杂志,20~(18),32(10):968-970.
[12]FLAMEN P,LERUT A,VAN CUTSEM E,et al.The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer[J].J Thorac Cardiovasc Surg,2000,120(6):1085-1092.
[13]BRUZZI J F,MUNDEN R F,TRUONG M T,et al.PET/CTof esophageal cancer:its role in clinical management[J].Radiographics,2007,27(6):1635-1652.
[14]HAN D,YU J,YU Y,et al.Comparison of ~(18)F-fluorothymidine and ~(18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus[J].Int JRadiat Oncol Biol Phys,2010,76(4):1235-1241.
[15]杭达明,成国建,储开岳,等.PET-CT对食管癌临床分期及在调强放疗中的应用[J].中华实用诊断与治疗杂志,2013,27(4):368-370.
[16]SHI W,WANG W,WANG J,et al.Meta-analysis of ~(18)FDGPET-CT for nodal staging in patients with esophageal cancer[J].Surg Oncol,2013,22(2):112-116.
[17]ZHU W,XING L,YUE J,et al.Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis[J].Br JRadiol,2012,85(1017):e694-e701.
[~(18)]MANDARD A M,DALIBARD F,MANDARD J C,et al.Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma:clinicopathologic correlations[J].Cancer,1994,73(11):2680-2686.
[19]Japan Esophageal Society.Japanese Classification of Esophageal Cancer,11th Edition:partⅡandⅢ[J].Esophagus,2017,14(1):37-65.
[20]DARNTON S J,ALLEN S M,EDWARDS C W,et al.Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy[J].J Clin Pathol,1993,46(1):51-55.
[21]VAN HAGEN P,HULSHOF M C,VAN LANSCHOT J J,et al.Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.
[22]MALTHANER R A,COLLIN S,FENLON D.Preoperative chemotherapy for resectable thoracic esophageal cancer[J].Cochrane Database Syst Rev,2006(3):D1556.
[23]BEUKINGA R J,HULSHOFF J B,VAN DIJK L V,et al.Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pretreatment ~(18)F-FDG PET/CT imaging[J].J Nucl Med,2017,58(5):723-729.
[24]KWEE R M.Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of ~(18)F-FDGPET:a systematic review[J].Radiology,2010,254(3):707-717.
[25]CHEN Y M,PAN X F,TONG L J,et al.Can ~(18)F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in esophageal cancer patients?A meta-analysis[J].Nucl Med Commun,2011,32(11):1005-1010.
[26]SCHREURS L M,JANSSENS A C,GROEN H,et al.Value of EUS in determining curative resectability in reference to CTand FDG-PET:the optimal sequence in preoperative staging of esophageal cancer?[J].Ann Surg Oncol,2016,23(Suppl 5):1021-1028.
[27]CONG L,WANG S,GAO T,et al.The predictive value of~(18)F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy:a meta-analysis[J].Jpn J Clin Oncol,2016,46(12):11~(18)-1126.
[28]MALIK V,LUCEY J A,DUFFY G J,et al.Early repeated~(18)F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus[J].J Nucl Med,2010,51(12):~(18)63-~(18)69.
[29]VAN HEIJL M,OMLOO J M,VAN BERGE H M,et al.Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer[J].Ann Surg,2011,253(1):56-63.
[30]NAKAJO M,JINGUJI M,NAKABEPPU Y,et al.Texture analysis of ~(18)F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy[J].Eur J Nucl Med Mol Imaging,2017,44(2):206-214.
[31]YANAGAWA M,TATSUMI M,MIYATA H,et al.Evaluation of response to neoadjuvant chemotherapy for esophageal cancer:PET response criteria in solid tumors versus response evaluation criteria in solid tumors[J].J Nucl Med,2012,53(6):872-880.
[32]DE COBELLI F,GIGANTI F,ORSENIGO E,et al.Apparent diffusion coefficient modifications in assessing gastrooesophageal cancer response to neoadjuvant treatment:comparison with tumour regression grade at histology[J].Eur Radiol,2013,23(8):2165-2174.
[33]魏路,姚峰.表观遗传调控在新辅助化疗中作用的研究进展[J].中华实用诊断与治疗杂志,20~(18),32(11):1141-1144.